Please try another search
For the three months ended 31 March 2016, Viamet Pharmaceuticals Holdings LLC revenues increased from $48K to $164K. Net loss applicable to common stockholders increased 79% to $12.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 76% to $7.5M (expense), Selling/General/Admin.
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Revenue | 0.16 | 0.31 | 0.37 | 0.05 |
Gross Profit | ||||
Operating Income | -9.5 | -8.51 | -21.6 | -5.39 |
Net Income | -10.82 | -10.45 | -22.22 | -6.01 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Assets | 39.5 | 31.98 | 39.52 | |
Total Liabilities | 6.94 | 10.47 | 7.92 | |
Total Equity | 32.56 | 21.51 | 31.6 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 3 Months |
Cash From Operating Activities | -9.79 | -26.65 | -18.41 | -5.52 |
Cash From Investing Activities | -0.26 | -0.29 | -0.23 | -0.02 |
Cash From Financing Activities | 15.76 | 35 | 35 | 0 |
Net Change in Cash | 5.72 | 8.06 | 16.36 | -5.54 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review